Summary of COVID-19 adalimumab studies

1. Fakharian et al., Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial

68 patient adalimumab late treatment RCT: no change in mortality (p=1), 33% higher ventilation (p=1), and no change in ICU admission (p=1).
RCT 68 hospitalized patients with severe COVID-19 showing no significant differences with adalimumab treatment.
Oct 2021, Int. Immunopharmacology, https://www.sciencedirect.com/science/article/pii/S156757692100597X, https://c19p.org/fakharian